IN-VITRO ACTIVITY OF A NEW ANTIFUNGAL TRIAZOLE, D0870, AGAINST CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS

被引:14
作者
BARCHIESI, F
COLOMBO, AL
MCGOUGH, DA
FOTHERGILL, AW
RINALDI, MG
机构
[1] AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284
[2] ESCOLA PAULISTA MED,SAO PAULO,BRAZIL
[3] UNIV ANCONA,IST MALATTIE INFETT & MED PUBBL,ANCONA,ITALY
关键词
D O I
10.1128/AAC.38.11.2553
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We investigated the in vitro activity of a new antifungal triazole, D0870, against 100 Candida albicans isolates from the oral cavities of patients infected,vith human immunodeficiency virus by using a broth macrodilution method following the recommendations provided by the National Committee for Clinical Laboratory Standards (document M27-P). All of the isolates were chosen from C. albicans isolates already tested for fluconazole susceptibility by the procedure of the National Committee for Clinical Laboratory Standards. Fifty isolates were considered fluconazole susceptible (MICs, less than or equal to 4 mu g/ml), and 50 isolates were considered fluconazole resistant (MICs, greater than or equal to 8 mu g/ml). The in vitro data demonstrated that D0870 had good activity against isolates tested; for 90% of all strains of C. albicans, MICs were 0.5 mu g/ml. However, the D0870 MICs for the fluconazole-susceptible isolates were lower than those for the fluconazole-resistant isolates; MICs for 50 and 90% of the isolates tested were less than or equal to 0.0078 and 0.06 mu g/ml, respectively, for fluconazole-susceptible isolates and 0.25 and 2 mu g/ml, respectively, for fluconazole-resistant isolates (P < 0.001). Our data suggest that this new triazole could represent a valid alternative in the treatment of oral candidiasis in human immunodeficiency virus-infected patients.
引用
收藏
页码:2553 / 2556
页数:4
相关论文
共 21 条
[1]   EMERGENCE OF CANDIDA-KRUSEI INFECTIONS AFTER THERAPY OF OROPHARYNGEAL CANDIDIASIS WITH FLUCONAZOLE [J].
AKOVA, M ;
AKALIN, HE ;
UZUN, O ;
GUR, D .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (07) :598-599
[2]   IN-VITRO ACTIVITY OF ITRACONAZOLE AGAINST FLUCONAZOLE-SUSCEPTIBLE AND FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BARCHIESI, F ;
COLOMBO, AL ;
MCGOUGH, DA ;
FOTHERGILL, AW ;
RINALDI, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1530-1533
[3]   CORRELATION OF IN-VITRO FLUCONAZOLE RESISTANCE OF CANDIDA ISOLATES IN RELATION TO THERAPY AND SYMPTOMS OF INDIVIDUALS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
CAMERON, ML ;
SCHELL, WA ;
BRUCH, S ;
BARTLETT, JA ;
WASKIN, HA ;
PERFECT, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2449-2453
[4]   ACTIVITIES OF THE TRIAZOLE D0870 INVITRO AND AGAINST MURINE BLASTOMYCOSIS [J].
CLEMONS, KV ;
HANSON, LH ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1177-1179
[5]   FLUCONAZOLE RESISTANT CANDIDA IN AIDS [J].
FOX, R ;
NEAL, KR ;
LEEN, CLS ;
ELLIS, ME ;
MANDAL, BK .
JOURNAL OF INFECTION, 1991, 22 (02) :201-204
[6]  
HITCHCOCK CA, 1987, J MED VET MYCOL, V25, P29
[7]  
HITCHCOCK CA, 1986, J GEN MICROBIOL, V132, P2421
[8]   IN-VITRO ACTIVITY OF THE NEW TRIAZOLE D0870 COMPARED WITH AMPHOTERICIN-B AND ITRACONAZOLE AGAINST ASPERGILLUS SPP [J].
MOORE, CB ;
LAW, D ;
DENNING, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (06) :831-836
[9]   IN-VITRO STUDIES OF A NEW ANTIFUNGAL TRIAZOLE, D0870, AGAINST CANDIDA-ALBICANS, CRYPTOCOCCUS-NEOFORMANS, AND OTHER PATHOGENIC YEASTS [J].
PENG, T ;
GALGIANI, JN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2126-2131
[10]   VARIATIONS IN FLUCONAZOLE SUSCEPTIBILITY AND ELECTROPHORETIC KARYOTYPE AMONG ORAL ISOLATES OF CANDIDA-ALBICANS FROM PATIENTS WITH AIDS AND ORAL CANDIDIASIS [J].
PFALLER, MA ;
RHINECHALBERG, J ;
REDDING, SW ;
SMITH, J ;
FARINACCI, G ;
FOTHERGILL, AW ;
RINALDI, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (01) :59-64